Q2 2015 13F Holders as of 30 Jun 2015
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
104,661,494
-
Total 13F shares
-
20,482,234
-
Share change
-
-51,094
-
Total reported value
-
$655,028,876
-
Price per share
-
$31.98
-
Number of holders
-
88
-
Value change
-
+$16,033,415
-
Number of buys
-
66
-
Number of sells
-
26
Institutional Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q2 2015
As of 30 Jun 2015,
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) was held by
88 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
20,482,234 shares.
The largest 10 holders included
Essex Woodlands Health Ventures, Inc., NQ HCIF GP, Ltd., FRANKLIN RESOURCES INC, Bank of New York Mellon Corp, JPMORGAN CHASE & CO, Polar Capital LLP, BlackRock Fund Advisors, Arrowpoint Asset Management, LLC, VANGUARD GROUP INC, and WADDELL & REED FINANCIAL INC.
This page lists
88
institutional shareholders reporting positions in this security
for the Q2 2015 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.